Some cases of thrombotic events combined with thrombocytopenia have been described after COVID-19 vaccination with AZD1222. This thrombotic disorder clinically resembles heparin-induced thrombocytopenia, with a different serological profile.
This analysis of the Sleep Heart Health Study showed that objective sleep efficiency, measured by polysomnography, was associated with risk of major adverse CV events and CVD mortality.
Prof. Kushner discusses the details of the STEP 1 trial, in which treatment with semaglutide was compared to placebo for the outcome of weight loss in adults with overweight or obesity without T2DM.
This analysis of n-of-1 trials showed no effect of atorvastatin on muscle symptoms compared to placebo in people who had previously reported muscle symptoms on statins.
Sodium intake was almost linearly associated with SBP and DBP, without a threshold for low or high sodium exposure. The effect of sodium reduction on BP was more pronounced in individuals with hypertension.
This study introduced an air pollution score to investigate the association between long-term joint exposure to various ambient air pollutants and risk of incident HF in the UK Biobank.
This study investigated the risk of incident CAD in participants from the UK Biobank with and without a family history of CVD in a sibling or parent.
This study used data from four community-based cohort studies and investigated the relation between SBP and incident CVD. Increasing CVD risk was observed beginning at lower SBP thresholds in women than in men.
The STEP 1 trial demonstrated a 15.3 kg weight loss and a sustained ≥5% reduction in body weight in 86.4% of participants after 68 weeks in individuals with overweight or obesity who were treated with semaglutide once-weekly.
Incidence of thrombotic complications remained high in hospitalized COVID-19 patients in the second wave. Thromboprophylaxis is therefore warranted in these patients.
Risk of overall mortality in COVID-19 patients was lower in the second wave, compared with the first wave. However, cumulative incidences of thrombotic complications remained high in the second wave.
From CANTOS to COLCOT to COPS to LoDoCo2: What are the lessons from these trials with anti-inflammatory treatment, in particular those with colchicine, in patients with residual inflammatory risk?